Press release
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host an investor event on Sunday, December 7, 2025 at 7:00 a.m. ET to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). These data will also be presented at the 67th American Society of Hematology (ASH) Annual Meeting. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Adult Sickle Cell Program and Assistant Professor at UVA School of Medicine, and Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register, please click here or visit the “Events and Presentations” section of Fulcrum’s website. A replay will be available on Fulcrum’s website following the event. The event will provide initial clinical data from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in SCD, and full data from the 12 mg dose cohort. A live question and answer session will follow the formal presentation. About Sheinei Alan, MD, PhDDr. Sheinei Alan earned her MD and PhD from Virginia Commonwealth University, followed by an internal medicine residency at Georgetown University. She currently serves as Director of the Inova Adult Sickle Cell Program—one of the most comprehensive in the region, caring for more than 250 adults with sickle cell disease—and as an Assistant Professor of Medicine at the University of Virginia School of Medicine – Inova Campus. As principal investigator for multiple cutting-edge clinical trials in sickle cell disease, Dr. Alan leads both industry-sponsored studies of novel therapeutic approaches and an internally funded investigation into cardiac complications in this patient population. A key member of the National Alliance of Sickle Cell Centers, she plays an active role in developing consensus guidelines, standardizing care nationwide, and creating pathways to train the next generation of sickle cell disease specialists. She also contributed her expertise to the NIH-funded, St. Jude–sponsored development of the Sickle Cell Outcomes Grading System (SCOGS). Dr. Alan has aut...